Quotes of All Topics . Occasions . Authors
Biotech research is incredibly important for health-care innovation.
We're at the beginning of the digitization and automation of biotech.
Biotech crops are not a solution to solve hunger in Africa or elsewhere.
Hype tends to precede the reality in biotech, but the reality does follow. Usually.
The biotech game is quickly changing. The people must demand their use of these treatments.
Biotech 1.0 is slow, like a lab science, and Version 2.0 is more like computational sciences.
We are working with a biotech company, Calypte, which has designed a urine test for the HIV antibody.
Biohackers want to tinker; do fun science; and, in the process, accelerate the pace of biotech innovation.
One of the things that launched the strength in biotech is when the pharmaceutical industry itself got a little slow.
One of the problems in the biotech world is the lack of women in leadership roles, and I'd like to see that change by walking the walk.
I'm an investor in a number of biotech companies, partly because of my incredible enthusiasm for the great innovations they will bring.
A lot of people said this was impossible. 'You can't build biotech for $50,000. You can't build anything for $50,000.' Well, that's no longer true, and we're proving it.
I don't think that a mutual fund that invests exclusively in biotech start-ups or invests exclusively in companies in Thailand offers any great safety or diversification.
Bioscience and biotech offer many opportunities. The U.S. focuses on the rich man; India has rich man diseases and poor man diseases. So you have a much larger set of opportunities.
We need people building companies all over the country to innovate in aviation, consumer products, education, health, cybersecurity, biotech, manufacturing, and everything in between.
I call myself an accidental entrepreneur. I was all set to take up a brewing job in Scotland when a chance encounter with an Irish entrepreneur led me to set up a biotech business in India instead.
It was a chance encounter with a biotech entrepreneur from Ireland that got me started as an entrepreneur in India, because I partnered this Irish company in setting up India's first biotech company.
I work in the tech industry and my husband works in biotech. He's head of IP for a company listed on the NASDAQ. And we have a lot of discussions in tech and biotech about the role of unionization in our industries.
Optimization tells us precisely how to diversify the portfolio, whether I should have 12% in semiconductors or 4% in biotech, etc., and it literally tells me how to diversify not only the industry groups but the stocks.
The really basic stuff that fuels 30-year job booms almost always comes from government research, stuff like biotech, the transistor, the Internet. The idea that private capital can handle the early spade work is a joke.
I support GMOs. And we should label them. We should label them because that is the very best thing we can do for public acceptance of agricultural biotech. And we should label them because there's absolutely nothing to hide.
The trouble is the field of science, medicine, universities, biotech companies - you name it - have been so splintered, layers, sub-divided, hacked that people can spend their entire career studying one tiny little cog of life.
When a nanotech company matures and becomes a real business, it becomes something else. It becomes a biotech company or a cleantech company or a memory chip company. Nanotechnology has fueled the core innovations in electronics and energy.
The first generation of biotech physically cut and pasted from one organism to another. You learned that taxol helped cure cancer, then you found the source organism and extracted the genes to make your drug. Now physical science is becoming information science.
Industries with rapid change are the enemy of the investor. Tech businesses, particularly biotech, is a problem from that point of view. All industries work with change, but you should ideally be investing in businesses with a low rate of change, not a high rate of change.
The development of exponential technologies like new biotech and AI hint at a larger trend - one in which humanity can shift from a world of constraints to one in which we think with a long-term purpose where sustainable food production, housing, and fresh water is available for all.
It's a great disappointment as a leader in the biotech industry that with all the amazing things the drug industry has done in the last couple of decades, we have not made a single major advance, have not not developed a single new chemical entity approved for the treatment for Alzheimer's disease.
